 |
|
|
| |
Week 48 results of EMERALD: A Phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults
|
| |
| |
Reported by Jules Levin
IDWeek2017/IDSA, October 4-8, 2017, San Diego
Chloe Orkin1, Joseph Eron2, Jean-Michel Molina3, Eugenia Negredo4, Joseph Gathe5,
Erika Van Landuyt6, Erkki Lathouwers6, Veerle Hufkens6, Romana Petrovic6, Magda Opsomer6,
on behalf of the EMERALD study group
1Barts Health NHS Trust, London, UK; 2The University of North Carolina School of Medicine, Chapel Hill, NC; 3Department of Infectious Diseases, St-Louis Hospital, University of Paris Diderot, Paris, France; 4Germans Trias i Pujol University Hospital, Badalona, Spain; 5Therapeutic Concepts, Houston, Texas, USA; 6Janssen Pharmaceutica NV, Beerse, Belgium
|
| |
|
|
|
|
|
